Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 2551 • 2014 ACR/ARHP Annual Meeting
Presence of Germinal Centers at Baseline Is Associated with Clinical Response of Glandular Essdai Domain after Abatacept Treatment in Primary Sjogren’s Syndrome
Erlin A. Haacke¹, Frans G.M. Kroese², Petra M. Meiners³, Bert van der Vegt¹, Arjan Vissink⁴, Fred K.L. Spijkervet³ and Hendrika Bootsma², ¹Pathology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ³Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁴Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: Abatacept inhibits the costimulatory interaction of T-lymphocytes and antigen-presenting cells. Treatment of early and active primary Sjögren's Syndrome (pSS) with abatacept decreases disease activity.…
Abstract Number: 985 • 2014 ACR/ARHP Annual Meeting
Labial Salivary Gland Antibody-Secreting Cell Specificity and Characteristics in Sjögren’s Patients
Kristi A. Koelsch¹, Jacen Maier-Moore², Kenneth Smith³, Christopher Lessard³, Astrid Rasmussen⁴, Biji Kurien³, Umesh Deshmukh³, A. Darise Farris³, Judith A. James⁵, Kathy L. Sivils⁴, R. Hal Scofield⁶ and Mark Coggeshall⁷, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, ²Dept. of Clinical Laboratory Science, University of Texas at El Paso, El Paso, TX, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁷Immunobiology and Cancer Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose Studies were approved by the OMRF and the University of Oklahoma Health Sciences Center Institutional Review Boards. Samples and data were obtained from 9…
Abstract Number: 2977 • 2014 ACR/ARHP Annual Meeting
Distinct Serum Protein Signature and Novel Biomarkers of primary Sjogren’s Syndrome Revealed by comprehensive High-Throughput Proteomic Analysis
Ayumi Nishikawa¹, Katsuya Suzuki², Yoshiaki Kassai³, Yuumi Gotou⁴, Takahiro Miyazaki³, Maiko Takiguchi⁵, Masaru Takeshita¹, Atsuko Murota², Rimpei Morita⁶, Akihiko Yoshimura⁶ and Tsutomu Takeuchi², ¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, ⁴Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Tokyo, Tokyo, Japan, ⁵Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Tokyo, Japan, ⁶Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: The EULAR SS Disease Activity Index (ESSDAI) is currently used as an objective evaluation method of clinical disease activity in clinical research into primary…
Abstract Number: 2550 • 2014 ACR/ARHP Annual Meeting
Impaired Speckle Tracking As a Marker of Subclinical Left Ventricular Dysfunction in Patients Affected By Primary Sjögren’s Syndrome
Fabiola Atzeni¹, Stefano Galaverna², Chiara Colombo², Luigi Gianturco², Laura Boccassini¹, Piercarlo Sarzi-Puttini¹ and Maurizio Turiel², ¹Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ²Cardiology Unit, IRCCS-Galeazzi Orthopedic Institute,, Milan, Italy
Background/Purpose Primary Sjögren’s syndrome (pSS) is a common chronic autoimmune disease that particularly affects the salivary and lachrymal glands, and leads to dry eyes and…
Abstract Number: 534 • 2014 ACR/ARHP Annual Meeting
Serum Biomarkers of Inflammation and Fibrosis in Advancing Diagnosis, Prognosis and Treatment of Anti-Ro Associated Congenital Heart Block
Amit Saxena¹, Peter M. Izmirly², Sung Won Han³, Andrew Markham⁴, Robert M. Clancy⁵ and Jill P. Buyon⁵, ¹Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Department of Population Health, New York University School of Medicine, New York, NY, ⁴Medicine, New York University School of Medicine, New York, NY, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose Women with Sjogren’s Syndrome (SS) and anti-Ro antibodies face the risk of a pregnancy complicated by fetal congenital heart block (CHB). Identification of maternal…
Abstract Number: 2979 • 2014 ACR/ARHP Annual Meeting
Nucleic Acid Sensing Receptors TLR7, RIG-I and MDA5 Collaborate in Driving the Systemic IFN Signature and Amplify the Pathogenic Loop: Potential New Targets for Therapy in Primary Sjogrens Syndrome
Naomi I Maria¹, Cornelia G. van Helden-Meeuwsen¹, Eline C. Steenwijk¹, Arne S. IJpma², Wouter Beumer¹, Zana Brkic¹, Virgil A. Dalm¹, Paul L. van Daele¹, P. Martin van Hagen¹, Peter J. van der Spek², Hemmo A. Drexhage¹ and Marjan A. Versnel¹, ¹Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ²Erasmus Medical Center, Bioinformatics, Rotterdam, Netherlands
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by autoantibodies targeting RNA-associated antigens, anti-SSA/SSB. The IFN-signature is present in over half of…
Abstract Number: 2546 • 2014 ACR/ARHP Annual Meeting
Metabolic Disorders Causing Fatigue in Sjogren’s Syndrome
Lakshmanan Suresh¹, Julian Ambrus², Long Shen³ and Sahana Vishwanath⁴, ¹60 Pineview Drive, State University of New York/Buffalo, Buffalo, NY, ²100 High St., University Of Buffalo, Buffalo, NY, ³Department of Medicine, SUNY at Buffalo, Buffalo, NY, ⁴Medicine, SUNY- Buffalo, buffalo, NY
Background/Purpose Sjogren’s syndrome (SS) is a complex disorder involving both the innate and immune system. Fatigue is a common feature of the disease. Mitochondrial dysfunction…
Abstract Number: 533 • 2014 ACR/ARHP Annual Meeting
Predictive Significance of CCL21 and CXCL13 Levels in the Minor Salivary Glands of Patients with Sjögren’s Syndrome
Kyung-Eun Lee¹, Dong-Jin Park¹ and Shin-Seok Lee², ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose Chemokines, which control inflammatory cell migration, have been shown to play important roles in the inflammatory processes associated with Sjögren’s Syndrome (SS). CCL21 and…
Abstract Number: 2981 • 2014 ACR/ARHP Annual Meeting
Prognostic Value of the Complex P2X7 Receptor-Inflammasome in Patients with Primary Sjögren’s Syndrome at Lymphoma Risk
Chiara Baldini¹, Eleonora Santini², Chiara Rossi², Francesca Sernissi¹, Daniela Martini¹, Alessia Gallo³, Valentina Donati², Nicoletta Luciano¹, Francesco Ferro¹, Illias Alevizos⁴, Anna Solini² and Stefano Bombardieri⁵, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Sjogren's Clinic, NIDCR, Bethesda, MD, ⁴NIDCR, Bethesda, MD, ⁵Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Pro-inflammatory P2X7-receptor has been recently implicated in the pathogenesis of primary Sjögren’s syndrome (pSS), suggesting that it may be involved in the initiation and…
Abstract Number: 2544 • 2014 ACR/ARHP Annual Meeting
How Does a Younger Age at the Onset of Sjögren’s Syndrome (pSS) Influence the Clinical Presentation and the Clinical Course of the Disease?
Chiara Baldini¹, Luca Quartuccio², Elena Bartoloni-Bocci³, Roberta Priori⁴, Francesco Carubbi⁵, Alessia Alunno³, Roberto Gerli³, Guido Valesini⁴, Salvatore De Vita² and Stefano Bombardieri⁶, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ³Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ⁴Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁵Rheumatology Clinic, University of L'Aquila, L'Aquila, Italy, ⁶Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: (1) To analyze the clinical presentation and the clinical course of Sjögren’s Syndrome (pSS) in Caucasian patients with an “early-onset” pSS and (2) to compare…
Abstract Number: 532 • 2014 ACR/ARHP Annual Meeting
Adipose Tissue Is Prominent in Salivary Glands of Sjögren’s Syndrome Patients and Appears to Influence the Autoimmune Microenvironment in These Organs
Kathrine Skarstein^1,2, Lara Adnan Aqrawi³, Roland Jonsson^4,5 and Janicke Cecilie Liaaen Jensen⁶, ¹Gade Laboratorium for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway, ²Department of Pathology, Haukeland University Hospital, Bergen, Norway, ³Department of Clinical Science, University of Bergen, Bergen, Norway, ⁴Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ⁵Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ⁶Department of Oral Surgery and Oral Medicine, University of Oslo, Oslo, Norway
Background/Purpose A positive salivary gland (SG) biopsy with a focus score of ≥1 is the only widely accepted pathological finding confirming the salivary gland component…
Abstract Number: 2929 • 2014 ACR/ARHP Annual Meeting
Molecular Diagnostics for Patient Subsetting in Sjögren’s Syndrome
John C. Hall¹, Alan N. Baer¹, Mi Y. Lam², Lindsey A. Criswell³, Antony Rosen¹ and Livia Casciola Rosen¹, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Orofacial Sciences, University of California San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA
Background/Purpose Sjögren’s syndrome (SS) is a chronic autoimmune disease which targets exocrine glands, particularly salivary and lacrimal glands. While all SS patients have abnormal secretory…
Abstract Number: 2543 • 2014 ACR/ARHP Annual Meeting
Anti-Ro/SSA Positive Incomplete Sjögren’s Syndrome
R. Hal Scofield¹, Anne Igoe², Donald U Stone³, Lida Radfar⁴, Kimberly S. Hefner⁵, David M. Lewis⁶, Stephen Young⁶, Judy Harris⁷, Kiely Grundahl⁷, Biji T. Kurien⁸, Jacen Maier-Moore⁹, Kristi A. Koelsch¹⁰, James Chodosh¹¹, Nelson L. Rhodus¹², Raj Gopalakrishnan¹³, Barbara M. Segal¹⁴, A. Darise Farris¹⁵, Courtney G. Montgomery¹⁶, Christopher J. Lessard¹⁷, Kathy L. Sivils¹⁸ and Astrid Rasmussen⁷, ¹US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ²Metro Health, Cleveland, OH, ³Dean McGee Eye Institute, Oklahoma City, OK, ⁴College of Dentristry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁶College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁹Dept. of Clinical Laboratory Science, University of Texas at El Paso, El Paso, TX, ¹⁰Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, ¹¹Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ¹²University of Minnesota, Minneapolis, MN, ¹³Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ¹⁴Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁵Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁷825 N.E. 13th St., Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a systemic disease characterized by dry eyes and mouth resulting from immune mediated damage and dysfunction of the lacrimal and…
Abstract Number: 526 • 2014 ACR/ARHP Annual Meeting
A Descriptive and Comparative Study of the Transcriptome from Salivary Exosomes of Sjögren’s Syndrome Patients Using RNA-Seq
Alessia Gallo¹, Mayank Tandon², Shyh-Ing Jang³, Ana Paola Cotrim⁴ and Ilias Alevizos⁵, ¹NIH, Bethesda, MD, ²Sjogren's Clinic, NIDCR, Bethesda, MD, ³Molecular Physiology and Therapeutics Branch, NIDCR, Bethesda, MD, ⁴NIDCR, NIH, Bethesda, MD, ⁵Sjogren's Clinic, NIDCR/ NIH #10 1N110, Bethesda, MD
Background/Purpose Saliva is a biofluid secreted by the salivary glands (SGs) that is critical for the health of the oral cavity. In Sjögren’s Syndrome (SS),…
Abstract Number: 2932 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Deep Vein Thrombosis and Pulmonary Embolism in Sjögren’s Syndrome: A General Population-Based Cohort Study
Marko Yurkovich¹, Hyon K. Choi², Eric C. Sayre³, Kamran Shojania⁴ and J. Antonio Avina-Zubieta⁵, ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Boston University School of Medicine, Boston, MA, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: There is limited data available on the risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) in Sjögren's Syndrome (SjS). We estimated the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.